PLX logo

Protalix BioTherapeutics (PLX) Cash From Operations

Annual CFO

-$1.32 M
+$23.68 M+94.73%

December 31, 2023

Summary

Performance

1-Year Change

+94.73%

3-Year Change

+94.95%

5-Year Change

+82.98%

15-Year Change

+86.81%

PLX Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

75.67%
PLX annual cash flow from operations is higher than 75.67% of companies in Healthcare sector

High & Low

All-time High

$44.45 M
PLX annual cash flow from operations is currently -102.96% below its historical high of $44.45 million

3-Year Low

-$25.00 M

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
PLX previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

Mar 14, 2025
PLX next annual earnings announcement is scheduled for Mar 14, 2025

OtherPLXcash flowmetrics:

Annual CFI

-$16.71 M
PLX annual cash flow from investing activities is -$16.71 million

Annual CFF

$24.67 M
PLX annual cash flow from financing activities is $24.67 million

Annual FCF

-$2.47 M
PLX annual free cash flow is -$2.47 million

Annual CAPEX

$1.15 M
PLX annual capital expenditures is $1.15 million

Quarterly CFO

$4.11 M
+$7.71 M+213.71%

September 30, 2024

Summary

Performance

3-Month Change

+213.71%

1-Year Change

+159.6%

3-Year Change

+159.6%

5-Year Change

+159.6%

PLX Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

78.08%
PLX quarterly cash flow from operations is higher than 78.08% of companies in Healthcare sector

High & Low

All-time High

$59.12 M
PLX quarterly cash flow from operations is currently -93.06% below its historical high of $59.12 million

3-Year Low

-$9.20 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
PLX previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 14, 2025
PLX next earnings announcement is scheduled for Mar 14, 2025

OtherPLXcash flowmetrics:

Quarterly CFI

$20.33 M
PLX quarterly cash flow from investing activities is $20.33 million

Quarterly CFF

-$20.42 M
PLX quarterly cash flow from financing activities is -$20.42 million

Quarterly FCF

$4.02 M
PLX quarterly free cash flow is $4.02 million

Quarterly CAPEX

$87.00 K
PLX quarterly capital expenditures is $87.00 thousand

TTM CFO

$8.28 M
+$10.99 M+404.90%

September 30, 2024

Summary

Performance

3-Month Change

+404.9%

1-Year Change

+210.02%

3-Year Change

+210.02%

5-Year Change

+210.02%

PLX TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

78.69%
PLX TTM cash flow from operations is higher than 78.69% of companies in Healthcare sector

High & Low

All-time High

$44.45 M
PLX TTM cash flow from operations is currently -81.38% below its historical high of $44.45 million

3-Year Low

-$27.48 M

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
PLX previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

Mar 14, 2025
PLX next earnings announcement is scheduled for Mar 14, 2025

OtherPLXcash flowmetrics:

TTM CFI

$19.20 M
PLX TTM cash flow from investing activities is $19.20 million

TTM CFF

-$20.42 M
PLX TTM cash flow from financing activities is -$20.42 million

TTM FCF

$7.17 M
PLX TTM free cash flow is $7.17 million

TTM CAPEX

$1.11 M
PLX TTM capital expenditures is $1.11 million

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

PLX Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+94.7%+159.6%+210.0%
3 y3 years+95.0%+159.6%+210.0%
5 y5 years+83.0%+159.6%+210.0%

PLX Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+94.7%-17.4%+144.6%at high+130.1%
5 y5-yearat high+95.0%-37.0%+141.7%at high+128.7%
alltimeall time-103.0%+96.6%-93.1%+134.8%-81.4%+121.5%

Protalix BioTherapeutics Cash From Operations History

DateAnnualQuarterlyTTM
Sep 2024
-
$4.11 M(-213.7%)
$8.28 M(-404.9%)
Jun 2024
-
-$3.61 M(-186.2%)
-$2.71 M(-146.3%)
Mar 2024
-
$4.19 M(+16.5%)
$5.87 M(-545.2%)
Dec 2023
-$1.32 M(-94.7%)
$3.60 M(-152.2%)
-$1.32 M(-82.5%)
Sep 2023
-
-$6.89 M(-238.5%)
-$7.52 M(-23.5%)
Jun 2023
-
$4.97 M(-265.9%)
-$9.84 M(-55.6%)
Mar 2023
-
-$3.00 M(+14.8%)
-$22.17 M(-11.3%)
Dec 2022
-$25.00 M(+143.1%)
-$2.61 M(-71.6%)
-$25.00 M(-9.0%)
Sep 2022
-
-$9.20 M(+25.1%)
-$27.48 M(+36.3%)
Jun 2022
-
-$7.36 M(+26.2%)
-$20.15 M(+220.9%)
Mar 2022
-
-$5.83 M(+14.6%)
-$6.28 M(-38.9%)
Dec 2021
-$10.29 M(-60.6%)
-$5.09 M(+170.6%)
-$10.29 M(-19.3%)
Sep 2021
-
-$1.88 M(-128.9%)
-$12.75 M(-11.9%)
Jun 2021
-
$6.52 M(-166.3%)
-$14.47 M(-49.8%)
Mar 2021
-
-$9.83 M(+30.3%)
-$28.82 M(+10.4%)
Dec 2020
-$26.11 M(+34.9%)
-$7.55 M(+109.5%)
-$26.11 M(+17.4%)
Sep 2020
-
-$3.60 M(-54.0%)
-$22.24 M(+1.7%)
Jun 2020
-
-$7.83 M(+10.1%)
-$21.86 M(+13.9%)
Mar 2020
-
-$7.12 M(+93.0%)
-$19.20 M(-0.8%)
Dec 2019
-$19.36 M(+150.0%)
-$3.69 M(+14.3%)
-$19.36 M(-1.6%)
Sep 2019
-
-$3.23 M(-37.6%)
-$19.68 M(+599.9%)
Jun 2019
-
-$5.17 M(-28.9%)
-$2.81 M(-49.8%)
Mar 2019
-
-$7.28 M(+81.7%)
-$5.61 M(-27.6%)
Dec 2018
-$7.74 M(-22.5%)
-$4.00 M(-129.4%)
-$7.74 M(-155.9%)
Sep 2018
-
$13.64 M(-271.3%)
$13.85 M(-234.1%)
Jun 2018
-
-$7.96 M(-15.4%)
-$10.33 M(-6.0%)
Mar 2018
-
-$9.41 M(-153.5%)
-$10.98 M(+9.9%)
Dec 2017
-$9.99 M(-68.9%)
$17.59 M(-266.9%)
-$9.99 M(-71.4%)
Sep 2017
-
-$10.54 M(+22.3%)
-$34.92 M(+25.5%)
Jun 2017
-
-$8.62 M(+2.3%)
-$27.83 M(-9.9%)
Mar 2017
-
-$8.43 M(+14.8%)
-$30.90 M(-3.7%)
Dec 2016
-$32.10 M(+32.2%)
-$7.34 M(+113.1%)
-$32.10 M(+12.2%)
Sep 2016
-
-$3.44 M(-70.6%)
-$28.62 M(-15.4%)
Jun 2016
-
-$11.69 M(+21.5%)
-$33.83 M(+23.1%)
Mar 2016
-
-$9.63 M(+149.5%)
-$27.49 M(+13.2%)
Dec 2015
-$24.28 M(-17.1%)
-$3.86 M(-55.5%)
-$24.28 M(-4.0%)
Sep 2015
-
-$8.66 M(+62.0%)
-$25.30 M(-3.4%)
Jun 2015
-
-$5.35 M(-16.7%)
-$26.19 M(-4.3%)
Mar 2015
-
-$6.42 M(+31.7%)
-$27.36 M(-6.6%)
Dec 2014
-$29.28 M(-4.5%)
-$4.87 M(-49.0%)
-$29.28 M(+0.5%)
Sep 2014
-
-$9.55 M(+46.5%)
-$29.15 M(+4.8%)
Jun 2014
-
-$6.52 M(-21.8%)
-$27.82 M(-5.4%)
Mar 2014
-
-$8.34 M(+75.9%)
-$29.41 M(-4.1%)
Dec 2013
-$30.65 M(-4927.2%)
-$4.74 M(-42.3%)
-$30.65 M(+27.2%)
Sep 2013
-
-$8.22 M(+1.3%)
-$24.09 M(+0.8%)
Jun 2013
-
-$8.11 M(-15.4%)
-$23.90 M(+795.2%)
Mar 2013
-
-$9.59 M(-626.4%)
-$2.67 M(-520.5%)
Dec 2012
$635.00 K(-102.7%)
$1.82 M(-122.7%)
$635.00 K(-108.1%)
Sep 2012
-
-$8.03 M(-161.2%)
-$7.80 M(-1.5%)
Jun 2012
-
$13.12 M(-308.9%)
-$7.92 M(-69.4%)
Mar 2012
-
-$6.28 M(-5.0%)
-$25.86 M(+9.7%)
Dec 2011
-$23.57 M
-$6.61 M(-18.8%)
-$23.57 M(-5.7%)
Sep 2011
-
-$8.15 M(+68.9%)
-$24.99 M(-5.8%)
DateAnnualQuarterlyTTM
Jun 2011
-
-$4.82 M(+20.9%)
-$26.52 M(-20.8%)
Mar 2011
-
-$3.99 M(-50.3%)
-$33.51 M(-12.9%)
Dec 2010
-$38.46 M(-186.5%)
-$8.03 M(-17.0%)
-$38.46 M(-234.1%)
Sep 2010
-
-$9.68 M(-18.0%)
$28.68 M(-13.0%)
Jun 2010
-
-$11.81 M(+32.0%)
$32.95 M(-20.6%)
Mar 2010
-
-$8.95 M(-115.1%)
$41.49 M(-6.7%)
Dec 2009
$44.45 M(-377.6%)
$59.12 M(-1192.6%)
$44.45 M(-363.0%)
Sep 2009
-
-$5.41 M(+65.3%)
-$16.91 M(-5.2%)
Jun 2009
-
-$3.27 M(-45.3%)
-$17.82 M(-2.0%)
Mar 2009
-
-$5.98 M(+167.2%)
-$18.19 M(+13.6%)
Dec 2008
-$16.02 M(+53.3%)
-$2.24 M(-64.6%)
-$16.02 M(-9.2%)
Sep 2008
-
-$6.33 M(+73.9%)
-$17.64 M(+35.6%)
Jun 2008
-
-$3.64 M(-4.4%)
-$13.01 M(+14.1%)
Mar 2008
-
-$3.81 M(-1.4%)
-$11.40 M(+9.1%)
Dec 2007
-$10.45 M(+105.2%)
-$3.86 M(+127.1%)
-$10.45 M(+24.7%)
Sep 2007
-
-$1.70 M(-16.4%)
-$8.38 M(+8.8%)
Jun 2007
-
-$2.03 M(-28.8%)
-$7.70 M(+13.0%)
Mar 2007
-
-$2.86 M(+59.6%)
-$6.81 M(+33.8%)
Dec 2006
-$5.09 M(+58.8%)
-$1.79 M(+75.6%)
-$5.09 M(-20.9%)
Sep 2006
-
-$1.02 M(-11.1%)
-$6.44 M(+18.3%)
Jun 2006
-
-$1.15 M(+0.8%)
-$5.44 M(+26.2%)
Mar 2006
-
-$1.14 M(-63.7%)
-$4.31 M(+34.5%)
Dec 2005
-$3.21 M(+83.3%)
-$3.14 M(>+9900.0%)
-$3.21 M(+92.4%)
Sep 2005
-
-$21.40 K(+18.9%)
-$1.67 M(-1.3%)
Jun 2005
-
-$18.00 K(-41.0%)
-$1.69 M(-1.5%)
Mar 2005
-
-$30.50 K(-98.1%)
-$1.71 M(-2.0%)
Dec 2004
-$1.75 M(+1179.4%)
-$1.60 M(+3603.5%)
-$1.75 M(+888.1%)
Sep 2004
-
-$43.10 K(-0.9%)
-$177.00 K(+14.6%)
Jun 2004
-
-$43.50 K(-34.3%)
-$154.40 K(+0.5%)
Mar 2004
-
-$66.20 K(+173.6%)
-$153.70 K(+12.4%)
Dec 2003
-$136.70 K(-6.8%)
-$24.20 K(+18.0%)
-$136.70 K(-1.5%)
Sep 2003
-
-$20.50 K(-52.1%)
-$138.80 K(-1.6%)
Jun 2003
-
-$42.80 K(-13.0%)
-$141.00 K(+5.6%)
Mar 2003
-
-$49.20 K(+87.1%)
-$133.50 K(-8.9%)
Dec 2002
-$146.60 K(-81.4%)
-$26.30 K(+15.9%)
-$146.60 K(-89.9%)
Sep 2002
-
-$22.70 K(-35.7%)
-$1.45 M(-0.7%)
Jun 2002
-
-$35.30 K(-43.3%)
-$1.46 M(+90.1%)
Mar 2002
-
-$62.30 K(-95.3%)
-$766.10 K(-3.0%)
Dec 2001
-$789.40 K(+1386.6%)
-$1.33 M(+3844.9%)
-$789.50 K(-217.6%)
Sep 2001
-
-$33.60 K(-105.1%)
$671.60 K(+2.1%)
Jun 2001
-
$655.30 K(-864.6%)
$657.60 K(-1282.7%)
Mar 2001
-
-$85.70 K(-163.2%)
-$55.60 K(+4.7%)
Dec 2000
-$53.10 K(-96.2%)
$135.60 K(-384.9%)
-$53.10 K(-80.9%)
Sep 2000
-
-$47.60 K(-17.8%)
-$278.60 K(-55.4%)
Jun 2000
-
-$57.90 K(-30.4%)
-$625.30 K(-36.2%)
Mar 2000
-
-$83.20 K(-7.5%)
-$980.00 K(-30.4%)
Dec 1999
-$1.41 M(+54.8%)
-$89.90 K(-77.2%)
-$1.41 M(+6.8%)
Sep 1999
-
-$394.30 K(-4.4%)
-$1.32 M(+42.7%)
Jun 1999
-
-$412.60 K(-19.3%)
-$923.90 K(+80.7%)
Mar 1999
-
-$511.30 K
-$511.30 K
Dec 1998
-$909.50 K(+266.9%)
-
-
Dec 1997
-$247.90 K(+510.6%)
-
-
Dec 1996
-$40.60 K
-
-

FAQ

  • What is Protalix BioTherapeutics annual cash flow from operations?
  • What is the all time high annual CFO for Protalix BioTherapeutics?
  • What is Protalix BioTherapeutics annual CFO year-on-year change?
  • What is Protalix BioTherapeutics quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Protalix BioTherapeutics?
  • What is Protalix BioTherapeutics quarterly CFO year-on-year change?
  • What is Protalix BioTherapeutics TTM cash flow from operations?
  • What is the all time high TTM CFO for Protalix BioTherapeutics?
  • What is Protalix BioTherapeutics TTM CFO year-on-year change?

What is Protalix BioTherapeutics annual cash flow from operations?

The current annual CFO of PLX is -$1.32 M

What is the all time high annual CFO for Protalix BioTherapeutics?

Protalix BioTherapeutics all-time high annual cash flow from operations is $44.45 M

What is Protalix BioTherapeutics annual CFO year-on-year change?

Over the past year, PLX annual cash flow from operations has changed by +$23.68 M (+94.73%)

What is Protalix BioTherapeutics quarterly cash flow from operations?

The current quarterly CFO of PLX is $4.11 M

What is the all time high quarterly CFO for Protalix BioTherapeutics?

Protalix BioTherapeutics all-time high quarterly cash flow from operations is $59.12 M

What is Protalix BioTherapeutics quarterly CFO year-on-year change?

Over the past year, PLX quarterly cash flow from operations has changed by +$10.99 M (+159.60%)

What is Protalix BioTherapeutics TTM cash flow from operations?

The current TTM CFO of PLX is $8.28 M

What is the all time high TTM CFO for Protalix BioTherapeutics?

Protalix BioTherapeutics all-time high TTM cash flow from operations is $44.45 M

What is Protalix BioTherapeutics TTM CFO year-on-year change?

Over the past year, PLX TTM cash flow from operations has changed by +$15.80 M (+210.02%)